:: allon therapeutics
February 28, 2012

Global Markets Direct,2011년 11월 발행 「Allon Therapeutics Inc. : 제품 파이프 라인 리뷰」

November 18, 2011

Allon Therapeutics Inc. - Product Pipeline Review - H2 2011 Summary Global Market Direct's pharmaceuticals report,

Allon Therapeuticsby AllonTherapeutics 275 views · Thumbnail 1:01. Add to VantageClips - American Creek Resources Ltd.by VantageClips

Allon Therapeutics Inc. 506-1168 Hamilton St Vancouver, BC V6B 2S2 Tel: (604) 736-0634. Fax: (604) 736-1616. Contact Name Rick Smith. Industry 35201010

Company invites investors and analysts to log-on to March 3rd CEO presentationVANCOUVER, British Columbia, March 7, 2011 /PRNewswire/

September 2, 2011

Allon Therapeutics, Inc. company research & investing information. Find executives and the latest company news.

Latest Allon Therapeutics Share Price and News. A Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such

Allon Therapeutics Inc. (TSX: NPC) announced today that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company's lead

Pharmacy Choice | (Datamonitor via COMTEX) Allon Therapeutics Inc., a biotechnology company, has initiated a pivotal Phase II/III clinical trial

May 17, 2012

Allon Therapeutics Inc. announces its 2009 milestones and confirmed that the company's existing cash resources are sufficient to fund its business into 2011.

Allon Therapeutics Inc., a clinical-stage biotechnology company, has appointed Michael Gold as vice president of clinical development and

Allon Therapeutics, 506-1168 Hamilton Street, Vancouver, BC, V6B 2S2, Canada . new therapeutic developments in the field of neurodegenerative diseases.

Allon Therapeutics Inc. - Product Pipeline Review - H2 2011 : Market Research Report Allon Therapeutics Inc. - Product Pipeline Review - H2

December 22, 2011

Allon Therapeutics Inc. (TSX: NPC) announced that it has been granted a United States patent covering the use of Allon's drug candidates,

VANCOUVER, BRITISH COLUMBIA, Apr 06, 2010 (MARKETWIRE via COMTEX) --Allon Therapeutics Inc. /quotes/comstock/11t!e:npc (CA:NPC

Allon Therapeutics news and press releases about recent investments, fund and portfolio company news, new hires and events.

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/30/11 -- Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States

February 22, 2012

Thursday May 11, 8:30 am ET VANCOUVER, BRITISH COLUMBIA--( CCNMatthews - May 11, 2006) - Allon Therapeutics Inc. (TSX:NPC

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. announced today it has closed a financing agreement with Isar Pharma K/S , a

Jun 16, 2008 - Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism(R) clinical trial

Allon Therapeutics to Present New Data at Leerink Swann Alzheimers Conference. - Business Wire - April 03, 2007 - April 03, 2007

December 24, 2011

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative

26, 2010) - Allon Therapeutics Inc. (TSX:NPC) a nounced today commencement of a pilot clinical trial in the Company's program to develop its.

Get detailed financial information on Allon Therapeutics Inc. (TSE:NPC) including real-time stock quotes, historical charts & financial news, all for free!

Subscriptions. Get emailed when Allon Therapeutics Inc. is picked. Subscribe. Pricing & Charts. Lookup NPC.TO at Yahoo Finance · Feedback

February 29, 2012

Allon Therapeutics Inc Allon Logo Allon Therapeutics Inc. is a clinical stage

Allon Therapeutics Inc - Vancouver - phone number & address - BC - Research & Development Bureaus.

Allon Therapeutics Vancouver. Allon Therapeutics. Visit Website · Print · Email Friend · Download PDF · Report Listing · Bookmark and Share. Allon

Apr 3, 2007 - Allon Therapeutics Inc. (TSX NPC), The Neuro Protection Company (TM), announced today the publication of new preclinical data from additional

February 17, 2012

HL:Allon Therapeutics fiscal 2009 net loss cut to $7.3 million from $11.3 million@

Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Trial Gordon McCauley, Allon's President and CEO, said the Company expects to

Allon Therapeutics Releases First Quarter Operating Results.

12, 2011) - Allon Therapeutics Inc. (TSX:NPC) today provided an update on progress in its pivotal clinical trial in progressive supranuclear

January 4, 2012

CANADA - Neuro Discovery Inc (ND) acquired all the outstanding stock of Allon Therapeutics Inc, a biopharmaceutical company, in exchange for #.### mil ND

Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's disease,

Allon Therapeutics Inc. ©2008 Allon Therapeutics obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors

Today we will analyze the stock ALLON THERAPEUTICS INC (NPC.TO) for internet stock trading in the TO stock market, Stock Technical

December 24, 2011

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 06/06/11 — Allon Therapeutics Inc. (TSX: NPC) today announced it will receive the

Stock analysis for NPC:CN. Get stock price, historical stock charts & news for Allon Therapeutics Inc, in the Therapeutics industry.

Allon Therapeutics earnings per share revisions and analysts forecast | Toronto Stock Exchange: | Toronto Stock Exchange.

Allon Therapeutics Inc, 1168 Hamilton Street, Vancouver BC V6B 2S2, 604-736- 0634.

May 11, 2012

Preliminary animal and Phase II human trials have shown that Davunetide, a creation of Allon Therapeutics, Inc., has potential as a treatment

Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully achieved the enrollment objective of 300 patients in the phase 2/3

News and bulletins about Allon Therapeutics for biotechnology, life sciences, pharmacy, healthcare, diagnostics, bioinformatics, updated daily and relevant to

Contributing to the day's overall success were investors of Allon Therapeutics Inc. (TSX:NPC), who experienced a 6.87% up-tick accompanied

September 22, 2011

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. In Q1 2008, Allon's drug

Tag Archives: Allon Therapeutics the application by Merus to graduate to the TSXV, and the filing by Allon Therapeutics of a short-form preliminary prospectus.

Allon Therapeutics Inc. (TSX: NPC) is developing drugs that target neurodegenerative diseases like dementia, schizophrenia and Parkinson's

11.12.2011 15:00:30 - Fast Market Research recommends "Allon Therapeutics Inc. - Product Pipeline Review - H2 2011" from Global Markets Direct, now

August 16, 2011

Message Boards Settings Allon Therapeutics, Inc. Search : in. Allon Therapeutics , Inc. board, Stocks A category, Stocks (A to Z) category, All Yahoo! Message

Free Allon Therapeutics Stock charts (TSE:NPC). Historical, Intraday and Live Allon Therapeutics charts with more than 80 charting studies and tools.

Allon Therapeutics Inc. is a clinical stage biotechnology company focused o More To interact with Allon Therapeutics you need to sign up for Facebook first.

©2011 Allon Therapeutics Inc. 2. Statements Allon may eventually develop. Other risk factors These factors can be reviewed in Allon's public filings at www .

February 26, 2012

Significant reduction in levels of beta-amyloid and phosphorylated tau Significant behavioral outcome in animals. Allon Therapeutics Inc.

Preclinical research with Allon Therapeutics intranasal davunetide shows improved motor function in Parkinson's Disease model.

Dr. Illana Gozes is Chief Scientific Officer, Director of Allon Therapeutics Inc. She has Dr. Gozes is a founder of Allon Therapeutics and Professor of Clinical

Business: Allon Therapeutics Inc, Address: 1681 Chestnut St # 315, City: Vancouver, Province: British Columbia, Phone: 604-736-1616.

January 22, 2012

Allon Therapeutics Inc. (TSX:NPC) ("Allon Therapeutics" or the "Company") Prior to the Offering, Allon Therapeutics had 78.8 million common

H2 2011” provides data on the Allon Therapeutics Inc.'s research and Allon Therapeutics Completes Private Placement Of Common Shares For $3 Million

virsitil's photostream (99) · Logo Seaside Family Services; Identity Silver Dynamics; Logo Allon Therapeutics; Identity ShirtMagic; Identity Solid

Allon Therapeutics Inc. (NPC.TO) provided an update on progress in its pivotal clinical trial in progressive supranuclear palsy or PSP and

May 18, 2012

Allon Therapeutics, Inc. Closes $2.5 Million Investment to Advance Clinical Development from Market Wire.

Allon Therapeutics' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth"

Allon Therapeutics Inc. ©2011 Allon Introduction to Allon Therapeutics. ∎ What we do? Allon Therapeutics founded in 2001. ∎ Public

AIM Therapeutics Inc. Canada, Visit their website. Algiax Pharmaceuticals GmbH, Germany. Allon Therapeutics (Toronto Stock Exchange (TSX):NPC), Canada

April 12, 2012

Allon Therapeutics Inc. (TSX: NPC) today announced it will receive the Gold Leaf Award as the Early Stage Company of the Year (Health) from

Allon Therapeutics, Inc., (NPC) announced that the company's proprietary compound NAP has been shown in preclinical studies to be effective

Allon Therapeutics Aktie im Überblick: Kurs, Realtimekurs und Chart. Nachrichten und Diskussionen zu Allon Therapeutics (CA0197741089, NPC, A0DP1L)

Allon Therapeutics Ltd. NPC. Categories: Biotech. Share |. Printer-friendly version. Recent Shoutbox. Get your voice heard and Make a Post! There is no activity.

November 11, 2011

Allon Therapeutics Wins National Biotech Award VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 06/06/11 -- Allon Therapeutics Inc. (TSX: NPC) today

Navigation Options ----, -Allon Therapeutics Inc. -, Company News and Bulletins, Directors and *NPC, *Allon Therapeutics Inc. TSX Venture, DELIST

Comparison of Allon Therapeutics, Inc. and Direct Competitors Financial Ratios. 5.3. Allon Therapeutics, Inc. Cash Flow Statement Key Figures. Table 7.

Find financial news for Allon Therapeutics Inc. (TSE:NPC) using Google Finance.

September 29, 2011

Rick Smith Jr is the Director, Investor Relations Communications of Allon Therapeutics. Details from Lead411 could include email - @allontherapeutics. com,

Allon Therapeutics, Alzheimer's disease, Prof. Illana Gozes, _x0000_i1030. Allon Therapeutics, MCI/stroke, Prof. Allon Therapeutics, Schizophrenia, Prof.

Allon Therapeutics Inc. Product Pipeline Review H2 2011 Summary Global Market Direct s pharmaceuticals report, Allon Therapeutics Inc. - Product

Gordon McCauley of Allon Therapeutics Inc. with the award for Allon Therapeutics Inc. is focused on bringing to market innovative central nervous system

August 2, 2011

News on Allon Therapeutics (Ticker: NPC) continually updated from thousands of sources around the net.

The Allon Therapeutics Inc. (NPCUF) Competitors by Product report shows Allon Therapeutics Inc. products and services according to the actual sector or line of

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 2, 2011) -Allon Therapeutics Inc. (TSX:NPC) today announced its unaudited operating

Allon Therapeutics Appoints Steven Whitaker CMO.

August 15, 2011

Leadership | Allon Therapeutics Inc. Executive Team: Gordon C. McCauley President & Chief Executive Officer. Gordon McCauley was appointed President of

Discover the latest info about npc to summary for allon therapeutics inc yahoo finance and read our other article related to npc to summary for

Information provided by (Responsible Party): Allon Therapeutics Further study details as provided by Allon Therapeutics: Primary Outcome

Allon Therapeutics Inc. announced today commencement of a pilot clinical trial in the Company's program to develop its lead neuroprotective

May 2, 2012

Completed: On October 18, 2011, Allon Therapeutics completed public offering of 9767500 units at a price of CAD0.25 ($0.25) per unit,

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegernative

Add to. BTV Weekly Market Wrap: Oct 21by BusinessTelevision68 views · Thumbnail 1:01. Add to VantageClips Featuring Allon Therapeuticsby

Everything relating to Allon Therapeutics: compilations of facts, news, background knowledge, product information and market trends can be found here in the

September 6, 2011

Allon Therapeutics has announced its completion of the enrollment objective of 300 patients in the phase 2/3 pivotal clinical trial evaluating the

Allon Therapeutics Inc company profile in Vancouver, Canada. Our company profile report for Allon Therapeutics Inc includes business information such as

Allon Therapeutics Inc. (TSX: NPC) yesterday announced that the Phase Iia clinical trial of its lead candidate davunetide achieved measurable

Allon Therapeutics Releases First Quarter 2011 Operating Results Allon Therapeutics Inc. (TSX:NPC) today announced its unaudited

November 10, 2011

Allon Therapeutics Inc. company information, data and profile. Benchmark the business against its key industry competitors.

Allon Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs to treat neurodegenerative diseases. Its lead product,

2 Allon Therapeutics, Inc. Interview Questions, Click Next for Next Interview Question. Question #2: Tell me about a time you have failed at a project in your life.

Allon Therapeutics Inc. Announces New Findings Of Davunetide Allon Therapeutics Inc. announced new findings that 12 weeks of treatment

May 20, 2012

Allon Therapeutics Releases Q3 Operating Results and Provides Corporate Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Trial

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. announced today that its lead neuroprotective drug candidate, davunetide, has

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, is

VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- Allon Therapeutics Inc. , today announced that Gordon C. McCauley, President

October 20, 2011

EV / Revenue Use Average, NPC Allon Therapeutics Inc. DNA Genentech, Inc. Change, AMGN Amgen, Inc. Change, GILD Gilead Sciences, Inc. Change, CELG

Allon Therapeutics Announces Publication of davunetide Data Demonstrating Cognition Improvement in Schizophrenia Model.

Allon Therapeutics Inc (Other OTC Issues : NPCUF). Trade now · Add to Watchlist · Get chart · Print report. Find prices for: 0.23 unch Delayed. MORE ABOUT

Allon Therapeutics Inc See also: Detailed Chart | Financials | Filings.

December 19, 2011

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 18, 2011) - Allon Therapeutics Inc. (TSX:NPC) - THIS NEWS RELEASE IS INTENDED

VANCOUVER, April 24, 2007— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today released new data confirming

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results.

Allon Therapeutics Inc. (TSX: NPC), a clinical-stage biotechnology company focused on bringing to market innovative central nervous system

February 1, 2012

Allon Therapeutics Inc Allon Logo A STRONG FOUNDATION Find out why Allon's clinical development strategy identifies opportunities. UPDATE FROM CEO

Results 1 - 10 of 59 Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies.

Allon's detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry analysis.

Allon Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical,

August 21, 2011

Hoovers company profile of Allon Therapeutics Inc.. Find detailed business information such as key executives, financials and other corporate data on Allon

Xconomy Allon Treads Into the Great Unknown, Alzheimer's Disease, With New Kind of Drug. Vancouver, BC, May 18, 2011--Allon

Allon Therapeutics Inc. Therapeutic Competitor Report contains detailed information on pipelines by phase and therapeutic indication as well as management

Sign up for Twitter to follow Allon Therapeutics (@AllonT). The official Twitter site of Allon Therapeutics, Inc.

November 14, 2011

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused Allon Therapeutics Releases Q3 Operating Results and Provides

Allon Therapeutics Inc.: Pilot Clinical Trial Initiated to Evaluate Davunetide in Tau -Pathology Dementias from Market Wire.

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/20/11 -- Allon Therapeutics Inc. (TSX:NPC) announced today that it has successfully

Vantage Clips Featuring Allon Therapeutics. VantageClips Featuring Allon Therapeutics 1:01. VantageClips; Délka: 1:01; Zobrazení: 40; Štítky: vantagewire

August 8, 2011

Marketwire VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 5, 2010) - Allon herapeutics Inc. (TSX:NPC) President and CEO Gordon

NPCUF Allon Therapeutics Inc - Detailed financial news for NPCUF Allon Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the

Allon Therapeutics Inc. (Toronto:NPC) Contact Information Allon Therapeutics Inc . 506-1168 Hamilton St.

Allon Therapeutics, Inc. Interview Questions by Position. There are currently no Allon Therapeutics, Inc. interview questions by position. Submit one. Interviews

December 16, 2011

TradingMarkets | Allon Therapeutics Inc., a clinical-stage biotechnology company , has appointed Michael Gold as vice president of clinical

Allon Therapeutics Inc. (TSX: NPC) announced today that its lead neuroprotective drug candidate, davunetide, has been granted Fast Track

ALLON THERAPEUTICS INC. is a clinical stage biotechnology company developing drugs that protect agai.

Please note: More presenting companies to come, please

December 19, 2011

Comprehensive Real-Time News Feed for Allon Therapeutics.

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug

This page contains information about Allon Therapeutics Inc.(NPC)

Allon Therapeutics enrolls for frontal dementia trial | CenterWatch News Online.

December 25, 2011

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, has

Allon Therapeutics Inc. NPCUF (OTN). AD: Find a Broker; Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading

Allon Therapeutics Inc. : Stock quote, stock chart, quotes, analysis, advice, financials and news for share Allon Therapeutics Inc. | Nasdaq other OTC: NPC

Allon Therapeutics Inc: Business description, financial summary, 3yr and interim Allon Therapeutics Inc. announced that it has completed the previously

March 24, 2012

Find Research Analysis On Allon Therapeutics Inc. NPCUF Including Analyst Reports and Sector Reports.

Allon Therapeutics Inc., an early stage biotech company, engaged Epic PR to raise awareness of its company and neurodegenerative drugs with potential

Allon's Intellectual Property Portfolio Strengthened With Additional U.S. Patent 11 /30/2011 8:30:08 AM - Market Wire Canada. Allon Therapeutics Releases Q3

Symbol: NPC:CA, Name: Allon Therapeutics Inc., Title: Allon Therapeutics Inc. ( NPC:CA) Stock Quote.

October 21, 2011

The Allon Therapeutics Inc. (NPCUF) Company Profile report lists Allon of key business relationships for Allon Therapeutics Inc. are all available at the click of

AL-108 is being tested on Alzheimer's first, but they plan to try it for MS too, so I figure these Phase I safety studies won't have to be done all

Vancouver-based biotech company Allon Therapeutics Inc. has been awarded US$500000 in grants from the U.S. government to fund

On July 15, 2008, Allon Therapeutics Inc. (TSX:NPC), announced that it had completed its previously annonced bought deal public offering of common shares .

February 19, 2012

Allon Therapeutics Inc. - Product Pipeline Review - Q4 2010 provides data on the company's research and development focus. The report

Allon Therapeutics Share Price (NPC) Share Prices, Charts, News, Financials, and More - Digital Look.

Allon Therapeutics, a British Columbia-based clinical-stage biotechnology company that develops first drugs to combat the progression of

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results Aug 12, 2011. from Marketwire · Allon Therapeutics Provides Pivotal Study Update

November 10, 2011

Allon Therapeutics, Inc San Diego, corporate profile and product articles.

Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as

Allon Therapeutics Wins National Biotech Award from Market Wire.

Allon Therapeutics to list shares on the Toronto Stock Exchange. - Find CNW Group articles.

September 19, 2011

Allon Therapeutics Inc. - Product Pipeline Review - Q4 2010. Nov 2010 - 40 pages - $500. Allon Therapeutics Inc.-Therapeutic Competitors Report. Nov 2010

Allon Therapeutics Inc. ©2010 Allon Therapeutics Inc. 1 . ©2010 Allon Therapeutics Inc. 12. Davunetide: Allon's approach to a tau-therapeutic

VANCOUVER, BRITISH COLUMBIA, Sep 22, 2011 (Marketwire via COMTEX News Network) -

Allon Therapeutics Inc specializes in Laboratories-Research & Development and is located in Vancouver BC.

February 2, 2012

Sorry! Could not find what you're looking for. What are you looking for? Search the News. RSS PILLSCRIBE ON TWITTER · pillscribe: Indian biotech revenues

ALLON THERAPEUTICS INC (NPC:CN) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key

Company invites investors and analysts to attend interactive real-time virtual conferenceVANCOUVER, British Columbia, Feb. 28, 2011

Allon Therapeutics, Inc. Announces Presentation of Davunetide Data During 10th International Conference on Alzheimer's and Parkinson's Disease 3/11/2011

December 23, 2011

Company profile for Allon Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by therapy

Allon Therapeutics' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three

Allon Therapeutics Inc.-Company Report. Allon Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of

Aegerion Pharmaceuticals, Inc Aeolus Pharmaceuticals, Inc. Affimed Therapeutics AG Afraxis, Inc. Akebia Therapeutics, Inc Allon Therapeutics Inc. Allozyne Inc.

December 19, 2011

Allon Therapeutics. Vantage Clips Featuring Allon Therapeutics. Tags: News vantagewire Allon Therapeutics Allon Healthcare Pharma health Vantage Clips

Welcome to the company profile of Allon Therapeutics on LinkedIn. Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to

Allon Therapeutics Inc. Allon Therapeutics Inc. CEO Clips | June 21, 2010 Watch more videos from CEO Clips. Tags:. .allon. .therapeutics

Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology

January 7, 2012

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug

Facts and figures about Allon Therapeutics Inc., taken from Freebase, the world's database.

Dr Gozes is President of the Israel Society for Neuroscience (ISFN), the Scientific Founder and Chief Scientific Officer of Allon Therapeutics Inc. and the

Download Historical Stock Quotes for Allon Therapeutics Inc. [TSX,NPC] in a range of formats.

October 13, 2011

From Yahoo! Finance: VANCOUVER, BRITISH COLUMBIA-- -

For the three months ended March 31, 2010, research and development expenses were $2167911 compared to $1198936 for the same

Fasken Martineau is mentioned on TechFinance as legal counsel to GMP Securities L.P. in the matter of Allon Therapeutics' unit offering

Allon Therapeutics, a biotechnology company, has announced preclinical data demonstrating the potential of AL-309, the company's

September 19, 2011

Allon Therapeutics' AL-208 product successful in Phase I clinical trial.

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/20/11 -- Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully

Download Allon Therapeutics Q1 2011 Report pdf documents from

ALLON THERAPEUTICS INC (NPCUF:US) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key

May 11, 2012

Browse a daily summary of experts opinions on stocks and stock investment information.

Illana Gozes, PhD, Allon Therapeutics Inc. 9:35ñ9:55. The Discovery and Preclinical Progress of the Neuroprotective Peptide, davunetide, in the Treatment of

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), announces that the National Institutes of Health, Department of

Allon Therapeutics, Inc. develops drugs that protect against euro degenerative conditions such as Alzheimer's disease, mild cognitive impairment, traumatic

March 8, 2012

Allon Therapeutics Wins National Biotech Award [June 6, 2011 - 05:31 AM PST]: Jun. 6, 2011 (Marketwire Canada) -- VANCOUVER, BRITISH

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 20, 2011) - Allon Therapeutics Inc. (TSX: NPC) announced today that it has

VANCOUVER — Allon Therapeutics Inc. (TSX: NPC) announced today it has entered into a standby equity distribution agreement (SEDA) with

ㆍCompany, Allon Therapeutics Inc. ㆍCountry, Canada. ㆍSpecialty, Neurodegenerative disease (Alzheimer's disease, schizophrenia)

May 17, 2012

Allon Therapeutics Inc. - Company Report provides up to date insight into the structure and operations of privately - held pharmaceutical,

Get real-time stock quote for Allon Therapeutics Inc. NPCUF including chart, current price, historical price, news, financial statements, balance sheet, income

Allon Therapeutics Inc at 1168 Hamilton St, Vancouver, BC V6B 2S2.

Company profile for Allon Therapeutics Inc. in Vancouver,BC. Get accurate business information including key contacts, company financials and more in the

December 17, 2011

NPC Allon Therapeutics Inc. Allon Therapeutics Wins National Biotech Award.

Allon Therapeutics Inc. announced the appointment of Gordon C. McCauley to its Board of Directors. McCauley is President and Chief

Allon Therapeutics - Annual Sales, industry, address, phone, website, company overview, executives, and employee information listed in Spoke''s business

Allon Therapeutics Inc. today announced its unaudited operating results for the three months More Allon Therapeutics News from Topix »

March 9, 2012

Stock analysis for NPCUF:US. Get stock price, historical stock charts & news for Allon Therapeutics Inc, in the Therapeutics industry.

View all of Allon Therapeutics's Presentations. Industry Medical / Health Care; About Allon Therapeutics Inc. is a clinical-stage biotechnology company

Allon Therapeutics Inc. company profile,Allon Therapeutics Inc. Address:506- 1168 Hamilton St. VancouverBC V6B 2S2 Canada,Website:,Contact Person:

Gauge financial strength for ALLON THERAPEUTICS INC (NPC) by looking at snapshots of assets and liabilities through time. Detailed Balance Sheets with

November 30, 2011

July 09, 2008 - Allon Therapeutics Inc. (TSX: NPC), announced that it has been granted a United States patent covering composition, delivery

The Institute for the Study of Aging (ISOA) has invested in Allon Therapeutics, a start-up biotechnology company. Allon Therapeuti.

Allon Therapeutics. Clinical Phase II. Merz Pharmaceuticals. Pre-Clinical. Neurophage Pharmaceuticals. Pre-Clinical. NasVax. Pre-Clinical. Allon Therapeutics

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human

January 16, 2012

Allon Therapeutics. NPC; TSX; Other Services. Latest 0.27; CurrencyC$; Change --; Percent Change --; Volume --; Jan 9, 2012 1:47:30 PM TSX data delayed 15

Allon Therapeutics Inc. (TSX: NPC) yesterday announced that the Phase IIa clinical trial of its lead candidate davunetide achieved measurable

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results [ August 12, 2011 - 14:00 PM PST]: VANCOUVER, BRITISH

Allon Therapeutics is involved in the discovery, development and commercialization of drugs to treat neurodegenerative diseases that lead to memory loss and

October 30, 2011

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, has

Allon Therapeutics Inc. 506-1168 Hamilton Street VANCOUVER BC V6B 2S2 CANADA More information. Phone : 1 604 736 0634. Fax : 1 604 736 1616

Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Allon has obtained Orphan Drug and Fast Track Status in the U.S.

View performance charts for Allon Therapeutics Inc (). View Allon Therapeutics Inc share price charts. Hargreaves Lansdown gives you free access to research,

May 11, 2012

Allon Therapeutics Inc. ©2010 Allon Therapeutics Inc. 1. Allon Therapeutics Inc. Corporate Overview. ASENT Annual Meeting. February 2010

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 14, 2011) - THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED

Company Description: Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Its davunetide

VANCOUVER, B.C. — Allon Therapeutics Inc. today issued an update on the progress of the pivotal Phase 2/3 clinical trial that is evaluating

November 29, 2011

CHICAGO, ILLINOIS--(Marketwire - July 30, 2008) - Allon Therapeutics Inc.

Gordon McCauley, CEO of Vancouver's Allon Therapeutics receives the BIOTECanada Gold Leaf Award for 2011 Early Stage Company of the

Renewable Energy Financial News, Stocks, Companies, and Market Research.

Allon Therapeutics Inc.-Therapeutic Competitors Report, published March 2011, pages 57, Allon Therapeutics Inc.-Therapeutic Competitors Report Report

August 24, 2011

B2B - Directory · Register Your company · Contract Manufacturing · Contract Research · Companies by Sector · Drugs by Therapeutic Area · Advertisement

Allon Therapeutics Inc. ("Allon Therapeutics" or the "Company") (TSX:NPC) announced today that, further to its press release dated September

Allon Therapeutics Inc ★ , Vancouver, 6047361616.

Allon Therapeutics, a biotechnology company based in Vancouver, British Columbia, has named Dr. Michael Gold vice president of clinical

January 18, 2012

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. , today announced that its shareholders have approved the investment by Neuro Discovery II

Summary financial information on Allon Therapeutics Inc.

Allon Therapeutics Inc. (TSX: NPC) announced today that it has received a major grant from the Michael J. Fox Foundation for Parkinson's

Meanwhile, Xconomy profiled the Vancouver, Canada-based Allon Therapeutics, which believes its peptide davunetide is the most advanced

December 21, 2011

Allon Therapeutics. News · Allon, Genta programs win FDA fast-track status. Fierce Biotech. Allon Therapeutics · davunetide · fast track · FDA · Genta · Tesetaxel

Biotechnology start-up Allon Therapeutics has announced a $2.5 million financing round. Founded in 2002, the company has raised $250000

Allon Therapeutics Inc. reported today in its Second Quarter 2008 operating results that the Company achieved all its clinical and financial

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions

August 5, 2011

Allon Therapeutics Inc. (TSX: NPC) has announced the preclinical data which demonstrates the potential of AL-309. AL-309.

Allon Therapeutics Inc. announced it received the Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada, Canada's

The drug is in clinical development by Vancouver based Allon Therapeutics for Alzheimer's disease and other neurodegenerative disorders.

Allon Therapeutics, the Vancouver, BC-based developer of drugs for neurological disorders, said today it has raised $10 million from a limited

October 12, 2011

VANCOUVER, B.C. - Allon Therapeutics Inc. announced that it has successfully achieved the enrollment objective of 300 patients in the phase

Get FREE realtime stock quotes on all Canadian and American exchanges. Vantage Wire is offering free stock quotes, realtime TSX, TSX-V,

Vancouver, BC, December 8, 2011--Allon Therapeutics today announced that its shareholders have approved the investment by Neuro Discovery II Limited

Pharmacy Choice - Pharmaceutical News - Allon Therapeutics Releases Q3 Operating Results and Provides Corporate Update - December 17

February 23, 2012

Allon Therapeutics' lead drug to be fast tracked in U.S..

Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering the use of Allon's drug candidates

Find financial news for Allon Therapeutics Inc. (TSE:NPC) using

Dr. J. Steven Whitaker M. D. J. D, Allon Therapeutics, Inc., Vancouver, BC - Business Contact Information in Jigsaw's business directory. Jigsaw's business

November 21, 2011

Financial Post Allon Therapeutics Inc. Allon Therapeutics Inc. Canada's most disappointing tech stocks. While some Canadian technology stocks are climbing

Allon Therapeutics IncTSX/Alpha:NPCview on OTC Markets Group Inc - Grey Market » · Help. Symbol Lookup. No Matches were found for. Additional matches

Get the latest NPC stock information on the web. Get the latest stock quote and more - DailyFinance is your source for ALLON THERAPEUTICS

Joined hundreds of Canada's life sciences leaders to applaud Cardiome Pharma Corp., Allon Therapeutics and EnWave Corp., as the firms'

July 28, 2011

VANCOUVER, British Columbia -- Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of

Allon Therapeutics Inc. (TSX: NPC) CEO Interview. Posted by admin - 28/07/10 at 08:07 pm. This interview has expired. Click here to find stocks, with exciting

2, 2011) - Allon Therapeutics Inc. (TSX:NPC) announced today that a research project funded by the Michael J. Fox Foundation (MJFF) for

Allon Therapeutics Inc. 1681 Chestnut St # 315, Vancouver, British Columbia, V6J 4M6. Phone: 604-736-1616. Categories: Laboratories-research &

December 17, 2011

Allon Therapeutic Inc. (NPCUF.PK) shares jumped more than 40% yesterday. On Tuesday, the company said that a clinical trial of its drug

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 05/11/10 -- Allon Therapeutics Inc. (TSX: NPC) today announced publication of data from

Allon Therapeutics. Gordon McCauley, CEO of Allon Therapeutics (a publicly traded bio-tech company) speaks about his company's recent successes.

Stock quote, stock chart, quotes, analysis, advice, financials and news for share ALLON THERAPEUTICS | Nasdaq other OTC: NPC | Nasdaq other OTC.

August 11, 2011

Allon Therapeutics. Alistair Stewart, PhD. 22 Jun 2009 Bruce H Morimoto. 04 Jun 2009 Syndicate content. Latest News. Merck dumps Parkinson's program

Allon Therapeutics Inc. (NPC) - Financial and Strategic SWOT Analysis Review - new company profile published Allon Therapeutics Inc. (NPC)

Allon Therapeutics Inc operates in the Biological products exc. diagnostic sector. Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company

Find out the latest news headlines for ALLON THERAPEUTICS INC. (NPC.TO).

September 17, 2011

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. today released top-line results from an imaging study of schizophrenia patients

Allon Therapeutics Inc. Director, Investor Relations (604) 742-2540 or Cell: . TradingMarkets News for NPC,NPCUF - Allon Therapeutics AL-108 Human

Allon Therapeutics Inc. (TSX:NPC) is a Vancouver-based biotechnology company developing drugs that protect against neurodegenerative conditions such as

ALLON THERAPEUTICS INC (NPC:CN) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key competitors, stock

September 21, 2011

Allon Therapeutics - Allon Therapeutics Inc. is a clinical stage biotechnology company focused on commercializing high potential central nervous system drugs.

Send an email message to ALLON THERAPEUTICS INC. ALLON THERAPEUTICS INC is a Pharmaceutical Preparation Manufacturing company located in

Product profiles for late stage and clinical stage products of Allon Therapeutics Inc. with complete description of the product's developmental

Home | Login | Stockstream. Allon Therapeutics Inc. npc go to snapshot add to favorites. post next page. see all posts, Overall Quality 2+, Overall Quality 3+

December 17, 2011

VANCOUVER, BRITISH COLUMBIA, Nov 08, 2011 (MARKETWIRE via COMTEX) -- Allon Therapeutics Inc. /quotes/zigman/31763 CA:NPC

Allon Therapeutics Inc announced today that the results of the completed Phase Ib clinical trial of a new schizophrenia drug temporarily named

AL-108 is being developed by Allon Therapeutics (TSX: NPC), a Canadian biotechnology company located in Vancouver. The drug was

Vancouver-based biotech company Allon Therapeutics (TSX: NPC) said that it recieved $500000 in US government grants for its davunetide

November 11, 2011

Allon Therapeutics, Inc. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and

Allon Therapeutics Closes $20 Million Bought Deal Offering.

View the basic NPC.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare ALLON THERAPEUTICS INC. against other companies.

Stock List. ALLON THERAPEUTICS INC. (NPC). Listing Exchange: TSX. Quote: All data delayed 15 minutes. Bid Size, Bid Price, Ask Price, Ask Size, Last Price

January 25, 2012

US:NPCUF - Get Stock quote detail for Allon Therapeutics Inc. Stock quotes include the latest US:NPCUF market price and fundamental investing data, price.


Name:

Email:

Phone:

Info:

Copyright © 2010-2012 ashokremedies.com